FBIO

Business Context and Reporting Period

Company: Fortress Biotech, Inc. (FBIO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Fortress is a biopharmaceutical company focused on acquiring and advancing assets through a network of subsidiaries and partner companies. Key entities include Journey Medical Corporation (dermatology products), Mustang Bio (oncology), Avenue Therapeutics, and others. The company operates as a "smaller reporting company."

Key Financial Metrics

Note: Net income for the three and six months ended June 30, 2025, is significantly influenced by a non-recurring gain from the deconsolidation of a subsidiary (see Material Changes).

Material Changes vs. Prior Comparable Period

• Deconsolidation of Checkpoint Therapeutics: In May 2025, Fortress sold Checkpoint Therapeutics to Sun Pharma. This resulted in a $27.1 million gain recorded in "Other income (expense)" for both the three and six months ended June 30, 2025. Without this gain, the company would have reported a net loss.
• Revenue Growth: Net revenue increased 10% quarter-over-quarter and 6% year-over-year (six months). This was driven by the commercial launch of Emrosi (rosacea treatment) by partner Journey Medical, which generated $2.8 million in Q2 2025 revenue. This was partially offset by declining sales of Accutane due to generic competition.
• Expense Fluctuations:
  • Selling, General and Administrative (SG&A): Increased 86% quarter-over-quarter to $38.8 million. This spike is primarily due to $17.7 million in expenses at Checkpoint related to the Sun Pharma transaction (stock compensation vesting, legal fees, and transaction costs).
  • Research and Development (R&D): Decreased 36% quarter-over-quarter to $8.1 million, driven by reduced spending at Mustang and the transition of the dotinurad program at Urica to a third party.
• Debt Repayment: Proceeds from the Checkpoint sale triggered mandatory prepayments on the Oaktree Note. In Q2 2025, Fortress repaid $4.9 million in principal plus interest and fees.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Capital Resources: Management believes current cash ($74.4 million total; $38.1 million for the Parent Entity) is sufficient to fund operations for at least 12 months. However, the company expects to continue incurring operating losses and will require additional financing for future development.
• Preferred Stock Dividends: The Board paused monthly dividends on the 9.375% Series A Preferred Stock in July 2024. As of June 30, 2025, approximately $8.0 million in dividends are accrued but undeclared. This pause has rendered the company ineligible to use Form S-3 shelf registration statements, limiting its ability to raise capital efficiently.
• Debt Covenants: The company is subject to financial covenants under its Oaktree credit agreement, including a minimum liquidity requirement of $7.0 million and a minimum net sales test for Journey Medical. The company was in compliance as of June 30, 2025.
• Key Risks:
  • Revenue Concentration: Operating income relies heavily on Journey Medical's dermatology products (Emrosi, Qbrexza, Accutane). Several products face generic competition or lack patent protection.
  • Financing Constraints: Inability to use Form S-3 due to unpaid preferred dividends increases the cost and complexity of raising capital.
  • Development Risks: Many product candidates are in early stages. Failure in clinical trials or regulatory approvals could materially impact the business.
  • Third-Party Reliance: Heavy reliance on third-party manufacturers and CROs introduces supply chain and operational risks.
• Unusual Items: The $27.1 million gain on deconsolidation is a non-operating, non-recurring item. Additionally, Avenue Therapeutics recognized $1.4 million in "Other revenue" from the termination of a license agreement with AnnJi Pharmaceutical.

Investor Verification Checklist

• Verify the Sustainability of Net Income: Confirm that the reported net income is driven by the one-time Checkpoint sale gain and assess the underlying operating loss trajectory.
• Monitor Preferred Dividend Status: Track the $8.0 million in accrued dividends and the timeline for resuming payments, as this directly impacts the company's ability to access capital markets via Form S-3.
• Assess Journey Medical's Performance: Review sales trends for Emrosi versus the decline in Accutane to understand the durability of the revenue stream.
• Review Debt Covenant Compliance: Monitor the "Minimum Net Sales Test" for Journey and the "Liquidity Requirement" to ensure no events of default occur.
• Check Capital Raise Plans: Given the Form S-3 ineligibility, investigate the company's strategy for raising future capital (e.g., private placements, S-1 filings) and associated dilution risks.